{"title":"Tofacitinib: A Potential Dual-Action Agent in Resolving Generalized Granuloma Annulare and Modulating HIV Reservoirs.","authors":"Yao Lei, Xiao-Qin Wang, Bing-Jun Shi","doi":"10.1097/MJT.0000000000001890","DOIUrl":"10.1097/MJT.0000000000001890","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e479-e480"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145627296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Iohexol-Induced Toxic Epidermal Necrolysis: A Case Report and Review of the Literature.","authors":"Nour Elhouda Zouaoui, Fatma Zgolli, Asma Jerbi, Imen Aouinti, Israa Dahmani, Sihem El Aidli","doi":"10.1097/MJT.0000000000002178","DOIUrl":"10.1097/MJT.0000000000002178","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e429-e434"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nawazish Ali, Ahmed Mustafa Khawaja, Muhammad Sohaib, Mirbaz Khan, Aqib Ali, Deen Wali
{"title":"Research Directions After the DAPA-STEMI Trial.","authors":"Nawazish Ali, Ahmed Mustafa Khawaja, Muhammad Sohaib, Mirbaz Khan, Aqib Ali, Deen Wali","doi":"10.1097/MJT.0000000000002205","DOIUrl":"10.1097/MJT.0000000000002205","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e465-e466"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mapping the Global Clinical Trial Landscape of Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Perspectives.","authors":"Yun Liao, Yike Li, Lihua Feng","doi":"10.1097/MJT.0000000000002204","DOIUrl":"10.1097/MJT.0000000000002204","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e467-e469"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Spesolimab in Pregnancy: A Breakthrough Treatment for Coexisting Generalized Pustular Psoriasis and Hallopeau Acrodermatitis Continua.","authors":"Shi Yan, Ya Deng, Juan Gong","doi":"10.1097/MJT.0000000000002020","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002020","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"33 5","pages":"e443-e446"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nino Marzella, Nardine K Salgado, Hubert C Chua, Lorena Dima, Timothy Nguyen
{"title":"Uncomplicated Cure: The New Era of Gonorrhea Therapy With Oral Zoliflodacin.","authors":"Nino Marzella, Nardine K Salgado, Hubert C Chua, Lorena Dima, Timothy Nguyen","doi":"10.1097/MJT.0000000000002172","DOIUrl":"10.1097/MJT.0000000000002172","url":null,"abstract":"<p><strong>Background: </strong>Gonorrhea is a preventable and treatable infection caused by Neisseria gonorrhoeae , remaining a major public health concern because of antibiotic-resistant strains. A milestone was reached with zoliflodacin, the first therapeutic in its class in nearly 2 decades.</p><p><strong>Mechanism of action, pharmacodynamics and pharmacokinetics: </strong>Zoliflodacin is a first-in-class spiropyrimidinetrione antibacterial agent that targets type II topoisomerases DNA gyrase and topoisomerase IV enzymes essential for DNA synthesis. Its primary target is the GyrB subunit of DNA gyrase, rather than the GyrA or ParC subunits affected by fluoroquinolones. The area under the concentration-time curve/minimum inhibitory concentration is the primary pharmacokinetics and pharmacodynamics index associated with bacterial killing. Zoliflodacin binds approximately 83% to plasma proteins, undergoes extensive metabolism through cytochrome P450-mediated and non-P450-mediated pathways, has a low urinary excretion with a major fecal route elimination pathway, and an elimination half-life of around 5-6 hours.</p><p><strong>Clinical trials: </strong>Zoliflodacin demonstrated positive results for the treatment of uncomplicated urogenital gonorrhea in phase 2 and subsequently phase 3 trials. In a phase 2, multicenter, open-label RCT, the efficacy and safety of zoliflodacin was compared with ceftriaxone. Cure rates for urogenital infections were 96% (55/57) (2 g), 96% (54/56) (3 g), and 100% (28/28) (ceftriaxone). In a phase 3, multinational, open-label, noninferiority RCT, participants were randomly assigned (2:1) to receive a single 3 g oral dose of zoliflodacin or a single dose of 500 mg intramuscular injection of ceftriaxone plus 1 g oral azithromycin. The primary end point for microbiological cure was achieved in 90.9% (460/506) of patients on zoliflodacin compared with 96.2% (229/238) of the comparator, demonstrating noninferiority and good tolerability.</p><p><strong>Therapeutic advance: </strong>Oral zoliflodacin represents a novel option for the treatment of uncomplicated urogenital gonorrhea, including antibiotic-resistant strains, providing an important alternative therapy.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e395-e404"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148468463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dua Ali, Zainab Binte Ahmad, Muhammad Waqas, Sneha Vijay, Izma Kamran Ali, Muhammad Saad
{"title":"SGLT2i Use Reduces the Risk of COPD Exacerbations Compared With DPP4is in Patients With Diabetes and Concomitant COPD: A Systematic Review and Meta-Analysis.","authors":"Dua Ali, Zainab Binte Ahmad, Muhammad Waqas, Sneha Vijay, Izma Kamran Ali, Muhammad Saad","doi":"10.1097/MJT.0000000000002193","DOIUrl":"10.1097/MJT.0000000000002193","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e435-e438"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}